POTS Adrenergic Ab (CIHR Aims #1&2)

Launched by UNIVERSITY OF CALGARY · Feb 1, 2016

Keywords

ClinConnect Summary

This clinical trial is looking at a condition called Postural Tachycardia Syndrome (POTS), which affects how the body regulates blood flow and heart rate, especially when standing up. The researchers want to see if people with POTS have higher levels of certain antibodies that might be involved in this condition compared to people without POTS. The study is currently recruiting participants, specifically individuals aged 18 to 60, both men and women, who have been diagnosed with POTS, as well as healthy individuals who do not have this diagnosis.

To be part of the study, participants must be willing to provide consent and meet some specific requirements. For example, they cannot have certain health issues like severe heart or lung diseases, and they should not be smokers or highly trained athletes. Those who have been diagnosed with anxiety or are taking specific medications may also be excluded. If eligible, participants can expect to undergo tests that will help researchers learn more about POTS and how it affects them and others. This trial could contribute to better understanding and treatment options for this condition in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients who have been previously diagnosed with POTS
• • Control subjects (patients not diagnosed with POTS)
• • Age between 18 - 60 years
• • Males and Females (Give that \>80% of POTS patients are female, we will attempt to enroll a similar percentage of female control subjects)
• • Able and willing to provide consent
• Exclusion Criteria:
• • Smokers
• • Overt cause for postural tachycardia, i.e., acute dehydration
• • Significant cardiovascular, pulmonary, hepatic, or hematological disease by history or prior testing
• • Highly trained athletes
• • Subjects with somatization or severe anxiety symptoms will be excluded
• • Use of drospirenone (a spironolactone analogue) containing oral contraceptive agent
• • Hypertension defined as supine resting BP\>145/95 mmHg off medications or needing antihypertensive medication
• • Other factors which in the investigator's opinion would prevent the participant from completing the protocol, including poor compliance during previous studies or an unpredictable schedule
• • Unable to give informed consent